Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, this improvement lasted for up to 140 days after the single dose.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a proof-of-concept study with a single application of the anti-IL-33 antibody etokimab (ANB020) in 12 patients with moderate or severe AD, 33% of patients reached the primary end point EASI75 and 83% reached EASI50 (ref.68).”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Etokimab inhibited direct, as well as CXCR1-dependent, neutrophil migration in vitro.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Self-citationA role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
Salimi, M., Barlow, J. L., Saunders, S. P., Xue, L., Gutowska-Owsiak, D., Wang, X., Huang, L.-C., Johnson, D., Scanlon, S. T., McKenzie, A. N. J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130351 · Cited by 979 · cited 1×
“The IL-33/ST2 pathway contributes to inflammation associated with disorders including atopic dermatitis (AD) (7), asthma (8), inflammatory bowel disease (9), and arthritis (10, 11).”
BackgroundSelf-citationγ-Secretase-mediated proteolysis in cell-surface-receptor signalling
Fortini, M. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm910 · Cited by 824
TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation
Kim, B. S., Siracusa, M. C., Saenz, S. A., Noti, M., Monticelli, L. A., Sonnenberg, G. F., Hepworth, M. R., Van Voorhees, A. S., Comeau, M. R., & Artis, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005374 · Cited by 731 · cited 1×
“In murine models, either IL-33 or TSLP alone is sufficient to promote the development of AD-like inflammation (39).”
BackgroundSilverberg, J. I., & Hanifin, J. M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.031 · Cited by 604
IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G
Lefrançais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J.-P., & Cayrol, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115884109 · Cited by 594 · cited 1×
“Furthermore, IL-33 can be cleaved into active forms by neutrophil elastase and cathepsin G (21), implicating an inflammatory cycle.”
BackgroundThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation
Hayakawa, H., Hayakawa, M., Kume, A., & Tominaga, S.-I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704916200 · Cited by 546 · cited 1×
“The soluble IL-33 decoy receptor soluble ST2 (sST2) has been used in treating allergic diseases in model systems (27).”
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350
Cayrol, C., & Girard, J.-P. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155891 · Cited by 322
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation
Hong, H., Liao, S., Chen, F., Yang, Q., & Wang, D. (2020) · Allergy · doi:10.1111/all.14526 · Cited by 272
Metadata
- Authors
- Chen, Y.-L., Gutowska-Owsiak, D., Hardman, C. S., Westmoreland, M., MacKenzie, T., Cifuentes, L., Waithe, D., Lloyd-Lavery, A., Marquette, A., Londei, M., & Ogg, G.
- Affiliations
- University of Oxford (GB)
- MRC Human Immunology Unit, NIHR Biomedical Research Centre, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
- AnaptysBio, Inc. (United States) (US)
- Corresponding author
- Ogg, Graham
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-10-23
- Volume
- 11
- Issue
- 515
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2979421310
- Cited by
- 250
- References
- 46
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 38 · 2023: 31 · 2022: 48 · 2021: 50 · 2020: 37 · 2019: 1
- FWCI
- 34.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council (MCUU_0008/5)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, neutrophil migration, CXCR1, interleukin-8, eosinophils, skin inflammation, Eczema Area and Severity Index
- MeSH terms
- Interleukin-33, Antibodies, Monoclonal, Cell Movement, Dermatitis, Atopic, Eczema, Humans, Inflammation, Neutrophils, Skin, Interleukin-12, Receptors, Interleukin-8A, Extracellular Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. https://app.cochat.ai/papers/10.1126/scitranslmed.aax2945
- The paper
- Chen, Y.-L., Gutowska-Owsiak, D., Hardman, C. S., Westmoreland, M., MacKenzie, T., Cifuentes, L., Waithe, D., Lloyd-Lavery, A., Marquette, A., Londei, M., & Ogg, G. (2019). Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aax2945
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.